Safety and side effect profile of fluoxetine

Expert Opinion on Drug Safety

Volumn 3, Issue 5, 2004, Pages 495-504

  Wernicke, Joachim F ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Fluoxetine; Prozac ; Safety; Side effects

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 2D6; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; FLUOXETINE; FLUOXETINE PLUS OLANZAPINE; HEPARIN; HYPERICUM PERFORATUM EXTRACT; LEVODOPA; METOPROLOL; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; NORFLUOXETINE; OLANZAPINE; ORAL CONTRACEPTIVE AGENT; PETHIDINE; PLACEBO; PROPAFENONE; PSYCHOTROPIC AGENT; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SUMATRIPTAN; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; WARFARIN; ZIMELDINE;

AGITATION; AKATHISIA; ANOREXIA; ANXIETY DISORDER; APNEA; ASTHENIA; BLEEDING; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CHOREA; CLINICAL TRIAL; COMA; CONFUSION; CONSTIPATION; DEPRESSION; DIAPHORESIS; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; DRUG INFORMATION; DRUG INHIBITION; DRUG MEGADOSE; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG USE; DYSPEPSIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FEVER; FLACCID PARALYSIS; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HUMAN; HYPERREFLEXIA; HYPOGLYCEMIA; HYPOMANIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; LIBIDO DISORDER; MALAISE; MANIA; MENTAL DISEASE; METABOLIC DISORDER; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCLONUS; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; NEUTROPENIA; PARKINSONISM; QT PROLONGATION; REVIEW; RHINITIS; SCIENTIFIC LITERATURE; SEIZURE; SENSORY DYSFUNCTION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SHIVERING; SIDE EFFECT; SOMNOLENCE; SUICIDE; SUICIDE ATTEMPT; SWEAT GLAND DISEASE; SWEATING; SYNDROME; TARDIVE DYSKINESIA; TERATOGENICITY; TIC; TREMOR; VISUAL HALLUCINATION; WEIGHT REDUCTION; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; ADULT; BIOTRANSFORMATION; BIPOLAR DISORDER; CARDIOVASCULAR DISEASES; CHILD; COMORBIDITY; CYTOCHROME P-450 CYP2D6; DEPRESSION; DRUG INTERACTIONS; FEMALE; FLUOXETINE; GASTROINTESTINAL DISEASES; GENETIC PREDISPOSITION TO DISEASE; HALF-LIFE; HUMANS; MALE; MICROSOMES, LIVER; PREGNANCY; PREGNANCY COMPLICATIONS; SEROTONIN UPTAKE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SUBSTANCE WITHDRAWAL SYNDROME; SUICIDE;

EID: 4544236400     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740338.3.5.495     Document Type: Review

References (104)

1. WERNICKE JF: The side effect profile and safety of fluoxetine. J. Clin. Psychiatry (1985) 46(3 Pt 2):59-67.
2. BEASLEY CM, KOKE SC, NILSSON ME, GONZALES JS: Adverse events and treatment discontinuation in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin. Ther. (2000) 22:1319-1330.
3. SCHMIDT ME, FAVA M, ZHANG S, GONZALES J, RAUTE NJ, JUDGE R: Treatment approaches to major depressive disorder relapse. Part 1: dose increase. Pychother. Psychosom. (2002) 71(4):190-194.
4. ZAJECKA J, AMSTERDAM JD, QUITKIN FM et al.: Changes in adverse events reported by patients during 6 months of fluoxetine therapy. J. Clin. Psychiatry (1999) 60(6):389-394.
5. SIMON GE, HEILIGENSTEIN JH, GROTHAUS L, KATON W, REVICKI D: Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. J. Clin. Psychiatry (1998) 59:49-55.
6. FAVA M, HOOG SL, JUDGE RA, KOOP JB, NILSSON ME, GONZALES JS: Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. J. Clin. Pychopharmacol. (2002) 22(2):137-147.
7. MICHELSON D, LYDIARD RB, POLLACK MH et al.: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. Am. J. Psychiatry (1998) 155(11):1570-1577.
8. MONTGOMERY SA, DUFOUR H, BRION S et al.: The prophylactic efficacy of fluoxetine in unipolar depression. Br. J. Psychiatry (1988) 153(Suppl. 3):69-76.
9. REIMHERR FW, AMSTERDAM JD, QUITKIN FM et al.: Optimal length of continuation therapy in depression: a prospective assessment during long-term fluoxetine treatment. Am. J. Psychiatry (1998) 155:1247-1253.
10. TOLLEFSON GD: Adverse drug reactions/interactions in maintenance therapy. J. Clin. Pychiatry (1993) 54(Suppl.):48-58.
11. GILABERTE I, MONTEJO AL, DE LA GANDARA J et al.: Fluoxetine in the prevention of depressive recurrences: a double-blind study. J. Clin. Psychopharmacol. (2001) 21(4):417-424.
12. MICHELSON D, AMSTERDAM JD, QUITKIN FM et al.: Changes in weight during a 1 -year trial of fluoxetine. Am. J. Psychiatry (1999) 156(8):1170-1176.
13. FAVA M, JUDGE R, HOOG SL, NILSSON ME, KOKE SC: Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight during long-term treatment. J. Clin. Psychiatry (2000) 61(11):863-867.
14. ROSEN RC, LANE R, MENZA M: Effects of SSRIs on sexual function: a critical review. J. Clin. Psychopharmacol. (1999) 19(1):67-85.
15. NURNBERG HG, HENSLEY P, LAURIELLO J: Sildenafil in the treatment of sexual dysfunction induced by selective serotonin reuptake inhibitors: an overview. CNS Drugs (2000) 13(5):321-335.
16. WALDINGER MD, HENGEVELD MW, ZWINDERMAN AH, OLIVIER B: Effects of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine and sertraline. J. Clin. Pychopharmacol. (1998) 18(4):274-281.
17. MICHAEL A, MAYER C: Fluoxetine-induced anesthesia of vagina and nipples. Br. J. Psychiatry (2000) 176:299.
18. HENRY C, DEMONTES-MAINARD J: Avoiding drug-induced switching in patients with bipolar depression. Drug Saf. (2003) 26(5):337-351.
19. DAMORE J, STINE J, BRODY L: Medication-induced hypomania in Asperger's disorder. J. Am. Acad. Child Adolesc. Psychiatry (1998) 37(3):248-249.
20. GONZALEZ-PINTO A, IMAZ H, PÉREZ DE HEREDIA JL, GUITIERREZ M, MICÓ JA: Mania and tramadol-fluoxetine combination. Am. J. Psychiatry (2001) 158(6):965.
21. MUNDO E, WALKER M, CATE T, MACCIARDI F, KENNEDY JL: The role of serotonin transporter protein gene in antidepressant-induced mania in bipolar disorder: preliminary findings. Arch. Gen. Psychiatry (2001) 58:539-544.
22. PERLIS RH, MISCHOULSON D, JORDAN W et al.: Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psychiatry (2003) 54:879-883.
23. JIMÉNEZ-JIMÉNEZ FJ, MOLINA JA: Extrapyramidal symptoms associated with selective serotonin reuptake inhibitors. CNS Drugs (2000) 14(5):367-379.
24. JIMÉNEZ-JIMÉNEZ FJ, PUERTAS I, DE TOLEDO-HERAS M: Drug-induced myoclonus: frequency, mechanism and management. CNS Drugs (2004) 18(2):93-104.
25. AKAGI H, KUMAR TM: Akathisia: overlooked at a cost. Br. Med. J (2002) 324:1506-1507.
26. BEASLEY CM: Fluoxetine-dopamine interaction data. J. Clin. Psychiatry (1994) 55(2):77-78.
27. MATHEN D, MARSDEN CD, BHATIA KP: SSRI-induced reversal of levodopa benefit in two patients with dopa-responsive dystonia. Mov. Disord. (1999) 14(5):874-875.
28. PISANI F, OTERI G, COSTA C, DI RAIMONDO G, DI PERRI R: Effects of psychotropic drugs on seizure threshold. Drug Saf. (2002) 25(2):91-110.
29. BOURGEOIS J, THOMAS D, JOHANSEN T, WALKER DM: Visual hallucinations associated with fluoxetine and sertraline. J. Clin. Psychopharmacol. (1998) 18(6):482-483.
30. WILKINSON T, BEGG EJ, WINTER A, SAINSBURY R: Incidence and risk factors for hyponatraemia following treatment with fluoxetine or paroxetine in elderly patients. Br. J. Pharmacol. 47(2):211-217.
31. ROOSE SP, SPATZ E: Treatment of depression in patients with heart disease. J. Clin. Psychiatry (1999) 60(Suppl. 20):34-37.
32. BAKER B, DORIAN P, SANDOR P et al.: Electrocardiographic effects of fluoxetine and doxepin in patients with major depressive disorder. J. Clin. Pychopharmacol. (1997) 17:15-21.
33. VARRIALE P: Fluoxetine (Prozac®) as a cause of QT prolongation. Arch. Intern. Med. (2001) 161(4):612.
34. VILINSKY F, LUBIN A: Severe neutropenia associated with fluoxetine hydrochloride. Ann. Intern. Med. (1997) 127(7):573-574.
35. CAPELLÀ D, BRUGUERA M, FIGUERAS A, LAPORTE JR: Fluoxetine-induced hepatitis: why is postmarketing surveillance needed? Eur. J. Clin. Pharmacol. (1999) 55:545-546.
36. HENRY JA: Epidemiology and relative toxicity of antidepressant drugs in overdose. Drug Saf. (1997) 16(6):374-390.
37. WITCHEL HJ, HANCOX JC, NUTT DJ: Psychotropic drugs, cardiac arrhythmia, and sudden death. J. Clin. Pychopharmacol. (2003) 23:58-77.
38. TEICHER MH, GLOD C, COLE JO: Emergence of intense suicidal preoccupation during fluoxetine treatment. Am. J. Psychiatry (1990) 147:207-210.
39. TEICHER MH, GLOD C, COLE JO: Antidepressant drugs and the emergence of suicidal tendancies. Drug Saf. (1993) 8(3):186-212.
40. GUZE SB, ROBINS E: Suicide and primary affective disorders. Br. J. Psychiatry (1970) 117:437-438.
41. WARSHAW MG, KELLER MB: The relationship between fluoxetine use and suicidal behavior in 654 subjects with anxiety. J. Clin. Psychiatry (1996) 57(4):158-166.
42. LEON A, KELLER MB, WARSHAW MG et al.: Prospective study of fluoxetine treatment and suicidal behavior in affectively ill subjects. Am. J. Psychiatry (1999) 156:195-201.
43. HEALY D: Lines of evidence on the risks of suicide with selective serotonin reuptake inhibitors. Psychother. Pychosom. (2003) 72:71-79.
44. OHBERG A, VUORI E, KLAUKKA T, LOONQVIST J: Antidepressants and suicide mortality. J. Affect. Disord. (1998) 50:225-233.
45. TOLLEFSON GD, FAWCETT J, WINOKUR G et al.: Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders. Ann. Clin. Psychiatry (1993) 5(4):209-224.
46. CRUNDWELL JK: Fluoxetine and suicidal ideation - a review of the literature. Int. J. Neurosci. (1993) 68(1-2):73-84.
47. LAPIERRE YD: Suicidality with selective serotonin reuptake inhibitors: valid claim? J. Psychiatry Neurosci. (2003) 28(5):340-347.
48. JICK SS, DEAN AD, JICK H: Antidepressants and suicide. Br. Med. J. (1995) 310:215-218.
49. MÖLLER HJ: Antidepressants - do they decrease or increase suicidality? Pharmacopsychiatry (1992) 25:249-253.
50. WALSH MT, DINAN TG: Selective serotonin uptake inhibitors and violence: a review of the available evidence. Acta Psychiatr. Scand. (2001) 104(4):84-91.
51. WERNICKE JF, SAYLER ME, KOKE MS, PEARSON DK, TOLLEFSON GD: Fluoxetine and concomitantly centrally acting medication use in clinical trials of depression: the absence of an effect related to agitation and suicidal behavior. Depress. Anxiety (1997) 6:31-39.
52. KHAN A, KHAN S, KOLTS R, BROWN WA: Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. Am. J. Psychiatry (2003) 160:790-792.
53. BEASLEY CM, POTVIN JH, MASICA DN, WHEADON DE, DORNSEIF BE, GENDUSO LA: Fluoxetine: no association with suicidality in obsessive-compulsive disorder. J. Affect. Disord. (1992) 24(1):1-10.
54. WHEADON DE, RAMPEY AH, THOMPSON VL, POTVIN JH, MASICA DN, BEASLEY CM: Lack of association between fluoxetine and suicidality in bulimia nervosa. J. Clin. Psychiatry (1992) 53(7):235-241.
55. GOLDSTEIN DJ, RAMPEY AH, POTVIN JH, MASICA DN, BEASLEY CM: Analysis of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. J. Clin. Psychiatry (1993) 54(8):309-316.
56. RAMACHANDRI P: Treatment of major depressive disorder in children and adolescents. Br. Med. J. (2004) 328:3-4.
57. WILENS TE, COHEN L, BIEDERMAN J et al.: Fluoxetine pharmacokinetics in pediatric patients. J. Clin. Psychopharmacol. (2002) 22:568-575.
58. EMSLIE GJ, HEILIGENSTEIN JH, WAGNER KD et al.: Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(10):1205-1215.
59. BIRMAHER B, AXELSON DA, MONK K et al.: Fluoxetine for the treatment of childhood anxiety disorders. J. Am. Acad. Child Adolesc. Psychiatry (2003) 42(4):415-423.
60. GELLER DA, HOOG SL, HEILIGENSTEIN JH et al.: Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial. J. Am. Acad. child Adolesc. Psychiatry (2001) 40(7):773-779.
61. LIEBOWITZ MR, TURNER SM, PIACENTINI J et al.: Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J. Am. Acad. Child Adolesc. Psychiatry (2002) 41(12):1431-1438.
62. SOLAI LK, MULSANT BH, POLLOCK BG: Selective serotonin reuptake inhibitors for late-life depression, a comparative view. Drugs Aging (2001) 18(5):355-368.
63. GOLDSTEIN DJ, HAMILTON SH, MASICA DN, BEASLEY CM: Fluoxetine in medically stable, depressed geriatric patients: effect on weight. J. Clin. Psychopharmacol. (1997) 17(5):365-369.
64. HENDRICK V, STOWE ZN, ALTSHULER L, HWANG S, LEE E, HAYES D: Placental passage of antidepressant medication. Am. J. Psychiatry (2003) 160:993-996.
65. COHEN LS, NONACS R, VIGUERA AC, REMINICK A: Diagnosis and treatment of depression during pregnancy. CNS Spectr. (2004) 9(3):209-216.
66. HENDRICK V, SMITH LM, SURI R, HWANG S, HAYNES D, ALTSHULER L: Birth outcomes after prenatal exposure to antidepressant medication. Am. J. Obstet. Gynecol. (2003) 188:812-815.
67. LAINE K, HEIKKINEN T, EKBLAD U, KERO P: Effects of exposure to selective reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch. Gen. Psychiatry (2002) 60:720-726.
68. NULMAN I, ROVET J, STEWART DE et al.: Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective controlled study. Am. J. Psychiatry (2002) 159:1889-1895.
69. KELLER F, GRIESSHAMMER M, HÄUSSLER U, PAULUS W, SCHWARTZ A: Pregnancy and renal failure: the case for application of dosage guidelines. Drugs (2001) 61(13):1901-1920.
70. MISRI S, KOSTARAS X: Benefits and risk to mother and infant of drug treatment for postnatal depression. Drug Saf. (2002) 25(13):903-911.
71. CHAMBERS CD, ANDERSON PO, THOMAS RG et al.: Weight gain in infants breastfed by mother who take fluoxetine. Pediatrics (1999) 104(5):1120-1121.
72. ROOSE SP, GLASSMAN AH, ATTIA E, WOODBRIDGE S, GIARDINA MA, BIGGER JT: Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am. J. Psychiatry (1998) 155(5):660-665.
73. SAUER WH, BERLIN JA, KIMMEL SE: Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation (2003) 108:32-36.
74. AMSTERDAM JD, GARCIA-ESPANA F, FAWCETT J et al.: Blood pressure changes during short-term fluoxetine treatment. J Clin. Pychopharmacol. (1999) 19:9-14.
75. JORGE RE, ROBINSON RG, ARNDT S, STARKSTEIN S: Mortality and poststroke depression: a placebo-controlled trial of antidepressants. Am. J. Psychiatry (2003) 160:1823-1829.
76. SAWKA AM, BURGART V, ZIMMERMAN: Loss of hypoglycemia awareness in an adolescent with Type 1 diabetes mellitus during treatment with fluoxetine hydrochloride. J. Pediatr. (2000) 136: 394-396.
77. HOLLAND JC, ROMANO SJ, HEILIGENSTEIN JH, TEPNER RG, WILSON MG: A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. Psychooncology (1998) 7(4):291-300.
78. ARNOLD DH: The central serotonin syndrome: paradigm for psychotherapeutic misadventure. Pediatr. Rev. (2002) 23:427-432.
79. CHECHANI V: Serotonin syndrome presenting as hypotonic coma and apnea: potentially fatal complications of selective serotonin receptor inhibitor therapy. Crit. Care Med. (2002) 30(2):473-476.
80. LANGE-ASSCHENFELD C, WEIEGMANN H, HIEMKE C, MANN K: Serotonin syndrome as a result of fluoxetine in a patient with tramadol abuse: plasma level-correlated symptomatology. J. Clin. Psychopharmacol. (2002) 22(4):440-441.
81. JOFFE RT, SOKOLOV ST: Co-administration of fluoxetine and sumatriptan: the Canadian experience. Acta Psychiatr. Scand. (1997) 95(6):551-552.
82. TISSOT TA: Probable meperidine-induced serotonin syndrome in a patient with a history of fluoxetine use. Anesthesiology (2003) 98:1511-1512.
83. BUTTERWECK V: Mechanism of action of St John's wort in depression: what is known? CNS Drugs (2003) 17(8):539-562.
84. WILIAMSON EM: Drug interactions between herbal and prescription medicines. Drug Saf. (2003) 26(15):1075-1092.
85. TOHEN M, VIETA E, CALABRESE J et al.: Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar 1 depression. Arch. Gen. Psychiatry (2003) 60:1079-1088.
86. NAGUIB M, KOORN R: Interaction between psychotropics, anaesthetics and electroconvulsive therapy: implications for drug choice and patient management. CNS Drugs (2002) 16(4):229-247.
87. KOKE SC, BROWN EB, MINER CM: Safety and efficacy of fluoxetine in patients who receive oral contraceptive therapy. Am. J. Obstet. Gynecol. (2002) 187:551-555.
88. DE MAISTRE E, ALLART C, LECOMPTE T, BOLLAERT PE: Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors. Am. J. Med. (2002) 113:530-532.
89. SAYAL KS, DUNCAN-MCCONNELL DA, MCCONNELL HW, TAYLOR DM: Psychotropic interactions with warfarin. Acta Psychiatr. Scand. (2000) 102(4):250-255.
90. FORD MA, ANDERSON ML, RINDONE JP, JASKER DW: Lack of effect of fluoxetine on the hypoprothrombinemic response of warfarin. J. Clin. Psychopharmacol. (1997) 17(2):110-112.
91. MOURILHE P, STOKES PE: Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression. Drug Saf. (1998) 18(1):57-82.
92. SPINA E, SCORDO MG: Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging (2002) 19(4):299-320.
93. PRESKORN S, BAKER B: Fatality associated wth combined fluoxetine-amitriptyline therapy. JAMA (1997) 227(21):1682.
94. TRUJILLO P, STOKES PE: Antiarrhythmic agents: drug interactions of clinical significance. Drug Saf. (2000) 23(6):509-532.
95. BROWN CS, FARMER RG, SOBERMAN JE, EICHNER SF: Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin. Pharmacokinet. (2004) 43(1):33-56.
96. BARRETT J, MEEHAN O, FAHY T: SSRI and sympathomimetic interaction (letter). Br. J. Psychiatry (1996) 168(5):653.
97. ZAJECKA J, FAWCETT J, AMSTERDAM J et al.: Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J. Clin. Psychopharmacol. (1998) 18(3):193-197.
98. HADDAD PM: Antidepressant discontinuation syndromes: clinical relevance, prevention and management. Drug Saf. (2001) 24(3):183-197.
99. JUDGE R, PARRY MG, QUAIL D, JACOBSON JG: Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int. Clin. Psychopharmacol. (2002) 17(5):217-225.
100. ROSENBAUM JF, FAVA M, HOOG S, ASCROFT RC, KREBS WB: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol. Psychiatry (1998) 44:77-87.
101. EINBINDER E: Fluoxetine withdrawal? Am. J. Psychiatry (1995) 152(8):1235.
102. FAVA M, MC GRATH PJ, SHEU WP et al.: Switching to reboxetine: an efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine. J. Clin. Psychopharmacol. (2003) 23:365-369.
103. LU ML, LANE HY, CHANG WH: Selective serotonin reuptake inhibitor syndrome: precipitated by concomitant clozapine? J. Clin. Psychopharmacol. (1999) 19(4):386-387.
104. MICHELSON D, FAVA M, AMSTERDAM et al.: Interruption of selective serotonin reuptake inhibitor treatment: double-blind, placebo-controlled trial. Br. J. Psychiatry (2000) 176:363-368.